Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 13/20 | 0.41 |
| ▸ | TYK2 | P29597 | 12/20 | 0.41 |
| ▸ | JAK3 | P52333 | 10/20 | 0.41 |
| ▸ | JAK1 | P23458 | 9/20 | 0.41 |
| ▸ | STAT3 | P40763 | 5/20 | 0.41 |
| ▸ | STAT6 | P42226 | 3/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL673304 | 0.91 | NTRK1 (0.43) | NTRK1JAK2TYK2JAK3JAK1 | |
| SCHEMBL673270 | 0.89 | NTRK1 (0.41) | NTRK1JAK2TYK2JAK3JAK1 | |
| SCHEMBL1665276 | 0.88 | NTRK1 (0.45) | NTRK1JAK2JAK3JAK1STAT6 | |
| SCHEMBL14675807 | 0.87 | NTRK1 (0.35) | NTRK1JAK2TYK2JAK3JAK1 | |
| SCHEMBL670858 | 0.86 | STAT6 (0.43) | NTRK1JAK2TYK2JAK3JAK1 | |
| SCHEMBL672591 | 0.85 | NTRK1 (0.39) | NTRK1JAK2TYK2JAK3JAK1 | |
| SCHEMBL15122378 | 0.84 | NTRK1 (0.41) | NTRK1JAK2TYK2JAK3JAK1 | |
| SCHEMBL15122368 | 0.84 | NTRK1 (0.40) | NTRK1JAK2TYK2JAK3JAK1 | |
| SCHEMBL670314 | 0.83 | NTRK1 (0.41) | NTRK1JAK2TYK2JAK3JAK1 | |
| SCHEMBL15122383 | 0.83 | NTRK1 (0.39) | NTRK1JAK2TYK2JAK3JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130190292-A1 | HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS SELECTIVE JAK INHIBITORS | CELLZOME LIMITED (GB) | 2013-07-25 | — | — | US | claimed |
| EP-2606050-A2 | HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS SELECTIVE JAK INHIBITORS | Cellzome Limited (GB) | 2013-06-26 | — | — | EP | claimed |
| WO-2012022681-A2 | HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS SELECTIVE JAK INHIBITORS | CELLZOME LIMITED (GB) | 2012-02-23 | — | — | WO | claimed |
| US-9040545-B2 | Heterocyclyl pyrazolopyrimidine analogues as selective JAK inhibitors | CELLZOME LIMITED (GB) | 2015-05-26 | — | — | US | disclosed |
| US-9040545-B2 | Heterocyclyl pyrazolopyrimidine analogues as selective JAK inhibitors | CELLZOME LIMITED (GB) | 2015-05-26 | — | — | US | disclosed |
| US-9040545-B2 | Heterocyclyl pyrazolopyrimidine analogues as selective JAK inhibitors | CELLZOME LIMITED (GB) | 2015-05-26 | — | — | US | disclosed |
| US-20130190292-A1 | HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS SELECTIVE JAK INHIBITORS | CELLZOME LIMITED (GB) | 2013-07-25 | — | — | US | disclosed |
| US-20130190292-A1 | HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS SELECTIVE JAK INHIBITORS | CELLZOME LIMITED (GB) | 2013-07-25 | — | — | US | disclosed |
| US-20130190292-A1 | HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS SELECTIVE JAK INHIBITORS | CELLZOME LIMITED (GB) | 2013-07-25 | — | — | US | disclosed |
| EP-2606050-A2 | HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS SELECTIVE JAK INHIBITORS | Cellzome Limited (GB) | 2013-06-26 | — | — | EP | disclosed |
| WO-2012022681-A2 | HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS SELECTIVE JAK INHIBITORS | CELLZOME LIMITED (GB) | 2012-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190292-A1 | HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS SELECTIVE JAK INHIBITORS | JAK1, JAK3, JAK2 | NTRK1 4682/4885JAK2 3/4885TYK2 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.